Welcome to LookChem.com Sign In|Join Free
  • or
C37H70NO6P is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

99884-83-0

Post Buying Request

99884-83-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

99884-83-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 99884-83-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,9,8,8 and 4 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 99884-83:
(7*9)+(6*9)+(5*8)+(4*8)+(3*4)+(2*8)+(1*3)=220
220 % 10 = 0
So 99884-83-0 is a valid CAS Registry Number.

99884-83-0Downstream Products

99884-83-0Relevant academic research and scientific papers

Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety

Wissner,Schaub,Sum,Kohler,Goldstein

, p. 328 - 333 (2007/10/02)

Racemic analogues of platelet activating factor (PAF) in which the methylene bridge separating the phosphate and trimethylammonium moieties is altered in length (7a-f) have been prepared. Increasing the length of this bridge results in a progressive decrease in the hypotensive and platelet aggregation responses. Analogues in which the phosphocholine group is substituted with a methyl group (7h and 7i) or a phenyl group (5j) or in which the methylene bridge is replaced with a meta-substituted benzyl group (5k) have been prepared. With respect to both the blood pressure and platelet aggregation responses, 7i and 5k showed little if any changes in potency compared to racemic C16-PAF. While 7h is more potent than 1a with respect to both the hypotensive and platelet aggregation properties, 5j is less potent. Replacement of the phosphate moiety of C18-PAF with a phosphonate group leads to decreased activity in both assays. Analogue 11, in which the phosphocholine group has been replaced with a 4-(trimethylammonio)butoxy group, exhibited no detectable hypotensive or platelet aggregating activity. None of the analogues exhibited a separation of the blood pressure and platelet aggregation activities.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 99884-83-0